1. Maeda K, Yamana T, Takao Y, Mimura T, Katsuno H, Seki M, et al. Japanese Practice Guidelines for Fecal Incontinence Part 1-definition, epidemiology, etiology, pathophysiology and causes, risk factors, clinical evaluations, and symptomatic scores and QoL questionnaire for clinical evaluations-English version. J Anus Rectum Colon 2021;5:52–66.
3. Paquette IM, Varma MG, Kaiser AM, Steele SR, Rafferty JF. The American Society of Colon and Rectal Surgeons’ clinical practice guideline for the treatment of fecal incontinence. Dis Colon Rectum 2015;58:623–36.
4. Wald A. Update on the management of fecal incontinence for the gastroenterologist. Gastroenterol Hepatol (N Y) 2016;12:155–64.
5. Vaizey CJ, Kamm MA, Bartram CI. Primary degeneration of the internal anal sphincter as a cause of passive faecal incontinence. Lancet 1997;349:612–5.
6. Mimura T, Yamana T, Takao Y, Seki M, Endo T, Katsuno H, et al. Current situation of the management of fecal incontinence in Japanese Institutions: diagnosis and treatment. J Jpn Soc Coloproctol 2012;65:101–8.
7. Morgan R, Patel B, Beynon J, Carr ND. Surgical management of anorectal incontinence due to internal anal sphincter deficiency. Br J Surg 1997;84:226–30.
9. Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev 2013;(2): CD007959.
10. Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M, et al. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet 2011;377:997–1003.
13. La Torre M, Lisi G, Milito G, Campanelli M, Clementi I. Sphinkeeper
TM for faecal incontinence: a preliminary report. Colorectal Dis 2020;22:80–5.
15. Shi Z, Zhou J, He X. On treatment of third-degree internal hemorrhoids with “Xiaozhiling” injection. J Trad Chin Med 1981;1:115–20.
17. Takano M, Iwadare J, Ohba H, Takamura H, Masuda Y, Matsuo K, et al. Sclerosing therapy of internal hemorrhoids with a novel sclerosing agent: comparison with ligation and excision. Int J Colorectal Dis 2006;21:44–51.
18. Hachiro Y, Kunimoto M, Abe T, Kitada M, Ebisawa Y. Aluminum potassium sulfate and tannic acid (ALTA) injection as the mainstay of treatment for internal hemorrhoids. Surg Today 2011;41:806–9.
20. Hachiro Y, Kunimoto M, Abe T, Kitada M, Ebisawa Y. Aluminum potassium sulfate and tannic acid injection in the treatment of total rectal prolapse: early outcomes. Dis Colon Rectum 2007;50:1996–2000.
21. Abe T, Hachiro Y, Kunimoto M. Combined aluminum potassium sulfate and tannic acid sclerosing therapy and anal encirclement using an elastic artificial ligament for rectal prolapse. Dis Colon Rectum 2014;57:653–7.
22. Abe T, Kunimoto M, Hachiro Y, Ebisawa Y. Injection sclerotherapy using aluminum potassium sulfate and tannic acid in the treatment of symptomatic rectocele: a prospective case series. Int J Surg 2016;30:94–8.
24. Hachiro Y, Abe T, Kunimoto M, Satoh Y, Tsuruma T. Effect of ALTA therapy for internal hemorrhoids on anal functions. J Jpn Soc Coloproctol 2012;65:39–42.
25. Bordeianou LG, Carmichael JC, Paquette IM, Wexner S, Hull TL, Bernstein M, et al. Consensus Statement of definitions for anorectal physiology testing and pelvic floor terminology (Revised). Dis Colon Rectum 2018;61:421–7.
26. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum 1993;36:77–97.
27. Hong KD, Kim JS, Ji WB, Um JW. Midterm outcomes of injectable bulking agents for fecal incontinence: a systematic review and meta-analysis. Tech Coloproctol 2017;21:203–10.
28. Koh CE, Solomon MJ. Injectable bulking agents for passive faecal incontinence. Tech Coloproctol 2013;17:343–4.